New hope for Hard-to-Treat breast cancer: Brain-Penetrating drug tested
NCT ID NCT07413939
First seen Feb 19, 2026 · Last updated Apr 29, 2026 · Updated 10 times
Summary
This study tests a new drug, RO7771950, designed to reach the brain, combined with standard therapies (trastuzumab and capecitabine) for people with advanced HER2-positive breast cancer that has spread or cannot be removed. It compares this new combo to another drug combo (tucatinib plus the same standard therapies). About 650 participants with or without brain metastases will be enrolled. The goal is to see which combo works better at stopping the cancer from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.